{"DataElement":{"publicId":"2426251","version":"1","preferredName":"Hormone Refractory Prostate Carcinoma Therapy Administration First Date","preferredDefinition":"the date of the first therapy for hormone refractory prostate cancer.","longName":"HO_RE_PR_TX_ADM_F_DT","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2426250","version":"1","preferredName":"Hormone Refractory Prostate Carcinoma Therapy Administration","preferredDefinition":"information related to the action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process for hormone refractory, not responding to treatment, prostate cancer.","longName":"HOR_REFR_PRST_TX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2425590","version":"1","preferredName":"Hormone Refractory Prostate Carcinoma","preferredDefinition":"Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various endocrine glands and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.:Refractory; not responding to treatment.:Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C2315:C38014:C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone","conceptCode":"C2315","definition":"Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various endocrine glands and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Refractory","conceptCode":"C38014","definition":"Not responding to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"049B5946-27C4-2FE1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-02","modifiedBy":"ONEDATA","dateModified":"2005-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2426248","version":"1","preferredName":"Therapy Administration","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:The act of administration.","longName":"C15368:C25409","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03E16831-B6F6-6D9B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-03","modifiedBy":"ONEDATA","dateModified":"2005-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03E16831-B6F7-6D9B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2016734","version":"3","preferredName":"First Date","preferredDefinition":"the first date of an assessment, test, or treatment.","longName":"FIRST_DT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"DATE","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"mm/dd/yyyy","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208018","version":"1","preferredName":"First Date","preferredDefinition":"Preceding all others in time or space or degree.:a particular day specified as the time something has, or will, happen.","longName":"C25509:C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3925-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A46DEB16-4336-34B0-E034-080020C9C0E0","latestVersionIndicator":"Yes","beginDate":"2004-10-05","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-06-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"ISO compliance.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811910","version":"1","longName":"Prostate","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CRF Text","type":"Preferred Question Text","description":"Date of first therapy for Hormone Refractory Prostate Cancer","url":null,"context":"CTEP"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"04AF34DC-067F-2BDB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-03","modifiedBy":"CAMPBELB","dateModified":"2008-04-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}